Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2015143126 A1 2015-09-24 [WO2015143126] / 2015-09-24
申请号/申请日
2015WO-US21421 / 2015-03-19
发明人
CHANG CHI-LONG;WU CHAO-CHIH;
申请人
DCB;MACKAY MEMORIAL HOSPITAL OF TAIWAN PRESBYTERIAN CHURCH & MACKAY MEMORIAL SOCIAL WORK FOUNDATION;
主分类号
IPC分类号
A01N-043/04A61K-039/00A61K-045/00
摘要
(WO2015143126) Disclosed herein are an immunogenic glycopeptide for inducing immune response to treat cancer.  Other aspects of the present disclosure are pharmaceutical composition comprising the immunogenic glycopeptide; and method for preventing and/or treating a cancer.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2014US-61955216 2014-03-19
主权利要求
(WO2015143126) Claims What is claimed is: 1. An immunogenic glycopeptide, wherein the immunogenic glycopeptide has the structure of:  wherein the PADRE is a pan-DR epitope and has at least 10 consecutive amino acid residues that is at least 80% identical to the amino acid sequence of AKXVAAWTLKAAA (SEQ ID No. 1), where X is a cyclohexylalanine residue; and wherein P is Globo H, GD2, GM2, SSEA 4, Lewis, LewisY or STn. 2. The immunogenic glycopeptide of claim 1, wherein the amino acid sequence of the PADRE is identical to the amino acid sequence of SEQ ID No. 1. 3. The immunogenic glycopeptide of claim 1, wherein P is Globo H, GM2, SSEA 4 or Lewis Y. 4. The immunogenic glycopeptide of claim 1, wherein the last residue (K) is omitted. 5. The immunogenic glycopeptide of claim 1, wherein the the first residue (A) or the first two residues (A and K) are omitted. 6. A pharmaceutical composition, comprising a therapeutically effective amount of one or more immunogenic glycopeptide of Claim 1 and a pharmaceutically acceptable carrier or adjuvant. 7. The pharmaceutical composition of Claim 6, wherein the adjuvant is QS21 or aluminum hydroxide. 8. The pharmaceutical composition of Claim 6, wherein the composition is a vaccine. 9. The pharmaceutical composition of Claim 8, wherein the vaccine is a polyvalent vaccine comprising one or more Globo H-, GM2-, Lewis Y, or SSEA4-PADRE glycopeptide as defined in Claim 1. 10. The pharmaceutical composition of Claim 9, wherein the polyvalent vaccine comprises Globo H-, GM2- and Lewis Y-PADRE glycopeptides or SSEA4-, GM2- and Lewis Y-PADRE glycopeptides. 11. A method for preventing and/or treating a cancer, comprises administering an effective amount of one or more immunogenic glycopeptide of Claim 1 to a subject. 12. A method for preventing and/or treating a cancer, comprises administering an effective amount of the pharmaceutical composition of Claim 6 to a subject. 13. A method for preventing and/or treating a cancer, comprises administering an effective amount of the pharmaceutical composition of Claim 9 to a subject. 14. A method for preventing and/or treating a cancer, comprises administering an effective amount of the pharmaceutical composition of Claim 10 to a subject. 15. The method of any of Claims 11 to 14, wherein the cancer is a tumor-associated carbohydrate-expressing cancer. 16. The method of Claim 15, wherein the cancer is breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer or lung cancer.
法律状态
(WO2015143126) LEGAL DETAILS FOR WO2015143126  Actual or expected expiration date=2017-09-19    Legal state=DEAD    Status=LAPSED     Event publication date=2015-03-19  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2015021421  Application date=2015-03-19  Standardized application number=2015WO-US21421     Event publication date=2015-09-24  Event code=WO/A1  Event type=Examination events  Published application with search report  Publication country=WO  Publication number=WO2015143126  Publication stage Code=A1  Publication date=2015-09-24  Standardized publication number=WO2015143126     Event publication date=2017-09-19  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE CA2943334  Actual or expected expiration date=2035-03-19    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=CA Corresponding appl: CA2943334  Application date in the designated or member state=2015-03-19   Application number in the designated or member state=2015CA-2943334 Corresponding cc:  Designated or member state=CA Corresponding pat: CA2943334  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2015-09-24   Publication number in the designated or member state=CA2943334    Event publication date=2016-09-13  Event code=WO/ENP  Event type=Entry into national phase  Entry into the national phase in: Corresponding cc:  Designated or member state=CA  LEGAL DETAILS FOR DESIGNATED STATE CN107073088  Actual or expected expiration date=2035-03-19    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=CN Corresponding appl: CN201580019341  Application date in the designated or member state=2015-03-19   Application number in the designated or member state=2015CN-80019341 Corresponding cc:  Designated or member state=CN Corresponding pat: CN107073088  Publication stage code in the designated or member state=A  Publication date in the designated or member state=2017-08-18   Publication number in the designated or member state=CN107073088 LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2016-09-19    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2016-09-19  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE EP3119424  Actual or expected expiration date=2035-03-19    Legal state=ALIVE    Status=PENDING   Corresponding cc:  Designated or member state=EP Corresponding appl: EP15764279  Application date in the designated or member state=2015-03-19   Application number in the designated or member state=2015EP-0764279 Corresponding cc:  Designated or member state=EP Corresponding pat: EP3119424  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2017-01-25   Publication number in the designated or member state=EP3119424    Event publication date=2016-09-23  Event code=WO/REEP  Event indicator=Pos  Event type=Entry into national phase  Request for entry into the European phase Corresponding cc:  Designated or member state=EP  LEGAL DETAILS FOR DESIGNATED STATE US2017143810  Actual or expected expiration date=2017-12-21    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=US Corresponding appl: US15126990  Application date in the designated or member state=2015-03-19   Application number in the designated or member state=2015US-15126990 Corresponding cc:  Designated or member state=US Corresponding pat: US2017143810  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2017-05-25   Publication number in the designated or member state=US20170143810    Event publication date=2016-09-16  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=US     Event publication date=2018-03-27  Event code=US/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=US
专利类型码
A1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部